ALK activation is present in all EIMS cases and in 50% of IMT cases, a finding that supports the tumorigenic origin of EIMS, as ALK proteins are recognized as oncogenic in both hematological and solid tumors. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.